Biofrontera Inc. — Major Shareholding Notification 2022

Feb 10, 2022

SC 13G 1 formsc13g.htm

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

Biofrontera Inc.

Field: Rule-Page

Field: /Rule-Page

(Name of Issuer)

Common Stock, par value $0.001 per share

Field: Rule-Page

Field: /Rule-Page

(Title of Class of Securities)

09077D 100

Field: Rule-Page

Field: /Rule-Page

(CUSIP Number)

December 31, 2021

Field: Rule-Page

Field: /Rule-Page

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

• The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

CUSIP No. 09077D 100 13G Page 2 of 5 Pages

| 1. | NAMES
OF REPORTING PERSONS Biofrontera
AG |
| --- | --- |
| 2. | CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see
instructions) (a)
☐ (b)
☐ |
| 3. | SEC USE ONLY |
| 4. | CITIZENSHIP
OR PLACE OF ORGANIZATION Germany |

| NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | SOLE
VOTING POWER 8,000,000 |
| --- | --- |
| 6. | SHARED
VOTING POWER 0 |
| 7. | SOLE
DISPOSITIVE POWER 8,000,000 |
| 8. | SHARED
DISPOSITIVE POWER 0 |

| 9. | AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 8,000,000 |
| --- | --- |
| 10. | CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☐ |
| 11. | PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 46.8%
(See Note 1) |
| 12. | TYPE
OF REPORTING PERSON (see instructions) CO |
| | Note
1: The denominator for this calculation is based on 17,104,749 shares of Biofrontera Inc. common
stock outstanding as of December 28, 2021, as reported in Biofrontera Inc.’s Current Report on Form 8-K filed with the U.S.
Securities and Exchange Commission on December 29, 2021. |

Field: Page; Sequence: 2

Field: /Page

CUSIP No. 09077D 100 13G Page 3 of 5 Pages

Item 1.

| (a) | Name
of Issuer Biofrontera
Inc. |
| --- | --- |
| (b) | Address
of Issuer’s Principal Executive Offices 120
Presidential Way, Suite 330 Woburn, MA 01801 |

Item 2.

| (a) | Name
of Person Filing Biofrontera
AG |
| --- | --- |
| (b) | Address
of the Principal Office or, if none, residence Hemmelrather
Weg 201, D-51377 Leverkusen
Germany |
| (c) | Citizenship Germany |
| (d) | Title
of Class of Securities Common
Stock, par value $0.001 per share |
| (e) | CUSIP
Number 09077D
100 |

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

| (a) | ☐ | Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o). |
| --- | --- | --- |
| (b) | ☐ | Bank
as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). |
| (c) | ☐ | Insurance
company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). |
| (d) | ☐ | Investment
company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). |
| (e) | ☐ | An
investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
| (f) | ☐ | An
employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
| (g) | ☐ | A
parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); |
| (h) | ☐ | A
savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
| (i) | ☐ | A
church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of
1940 (15 U.S.C. 80a-3); |
| (j) | ☐ | Group,
in accordance with §240.13d-1(b)(1)(ii)(J). |

Field: Page; Sequence: 3

Field: /Page

CUSIP No. 09077D 100 13G Page 4 of 5 Pages

Item 4. Ownership.

Explanatory Note : Prior to November 2, 2021, Biofrontera Inc. was a wholly owned subsidiary of the Reporting Person. On November 2, 2021, Biofrontera Inc. consummated its initial public offering (“IPO”) of 3,600,000 units, each consisting of (i) one share of common stock of Biofrontera Inc. and (ii) one warrant entitling the holder to purchase one share of Biofrontera Inc.’s common stock at an exercise price of $5.00 per share. The underwriters in the IPO exercised in full their option to purchase up to an additional 540,000 warrants to cover over-allotments. Immediately following the IPO, the Reporting Person owned 8,000,000 shares, or approximately 70.0%, of Biofrontera’s 11,600,000 then outstanding shares. On December 3, 2021, Biofrontera Inc. agreed to sell in a private placement to a single institutional investor, (i) 1,350,000 shares of Biofrontera Inc.’s common stock, (ii) a common stock purchase warrant to purchase up to 2,857,143 shares of Biofrontera Inc.’s common stock and (iii) a pre-funded common stock purchase warrant to purchase up to 1,507,143 shares of Biofrontera Inc.’s common stock. As of December 31, 2021, there were 17,104,749 shares of Biofrontera Inc.’s common stock outstanding as a result of the private placement and the exercise of a portion of the warrants issued in the private placement and the IPO.

(a)	Amount beneficially owned: 8,000,000 shares of Biofrontera Inc.’s common stock
(b)	Percent of class: 46.8%, The percent of class is based on a denominator of 17,104,749 shares of Biofrontera Inc. common stock outstanding as of December 28, 2021, as reported in Biofrontera Inc.’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on December 29, 2021.
(c)	Number
of shares as to which the person has:
	(i)	Sole
power to vote or to direct the vote . 8,000,000
	(ii)	Shared
power to vote or to direct the vote . 0
	(iii)	Sole
power to dispose or to direct the disposition of . 8,000,000
	(iv)	Shared
power to dispose or to direct the disposition of . 0

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Not applicable.

Field: Page; Sequence: 4

Field: /Page

CUSIP No. 09077D 100 13G Page 5 of 5 Pages

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 10, 2022

| BIOFRONTERA
AG | |
| --- | --- |
| By: | /s/
Ludwig Lutter |
| Name: | Ludwig
Lutter |
| Title: | Chief
Financial Officer |

Field: Page; Sequence: 5; Options: Last

Field: /Page